CTSO Stock UPDATES Cytosorbents Cor (CTSO) 0.2678 08/19/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cytosorbents Cor (CTSO) 0.2678 $CTSO

CytoSorbents Records Another Solid Quarter of Growth in Q2 2014
PR Newswire - Tue Aug 12, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat critically-ill patients in multiple countries worldwide, reported second quarter financial and operational results for the three and six months ended June 30, 2014.

CytoSorbents to Report Q2 2014 Operating and Financial Results
PR Newswire - Wed Aug 06, 8:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report Q2 2014 financial results after the market close on Tuesday, August 12, 2014.

CytoSorbents enters into distribution agreement for CytoSorb in Taiwan
M2 - Wed Aug 06, 6:33AM CDT
Immunotherapy company CytoSorbents (OTC BB:CTSO) said on Tuesday that it has signed a distribution agreement for its CytoSorb extracorporeal cytokine adsorber in Taiwan.

CytoSorbents Expands Distribution to Taiwan with Hemoscien Corporation
PR Newswire - Tue Aug 05, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced distribution of its CytoSorb® extracorporeal cytokine adsorber in Taiwan through an exclusive agreement with Hemoscien Corporation. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity.

First Publication Using CytoSorb® Therapy During Cardiac Surgery
PR Newswire - Thu Jul 17, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany.

CytoSorbents Consolidates SEC and International Legal Counsel with DLA Piper
PR Newswire - Wed Jul 09, 7:30AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced consolidation of its SEC and international legal counsel with the global law firm, DLA Piper LLP. DLA Piper is one of the largest international business law firms with offices in major markets around the world and legal expertise across a broad range of areas including corporate and finance, litigation and arbitration, Sarbanes Oxley compliance, government affairs, labor law, intellectual property and technology, and tax.

Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.

Merriman Capital Initiates Research Coverage on CytoSorbents Corporation
Thomson Reuters ONE - Thu Jun 19, 8:33AM CDT
SAN FRANCISCO - June 19, 2014 - Merriman Capital, Inc. ("Merriman" , a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of CytoSorbents Corporation (OTCQB: CTSO) with a Buy rating.

Cardica Inc. (CRDC) Soars: Stock Adds 10.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:21AM CDT
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise by over 10% on the day.

Oracle Hits New Yearly High; Cytosorbents Posts Record Q4 in 2013
ACCESSWIRE - Tue Apr 01, 12:57AM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL

CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue
PR Newswire - Mon Mar 31, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013.

CytoSorbents to Report Fiscal 2013 Operating and Financial Results
PR Newswire - Tue Mar 25, 6:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report fiscal 2013 financial results after the market close on Monday, March 31, 2014.

CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014
PR Newswire - Thu Mar 13, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:

CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.

Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista" announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.

National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.

Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies

CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014
Marketwire - Tue Jan 07, 8:01AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company, announced that it will exhibit its CytoSorb(R) and HemoDefend(TM) technologies at the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress from January 10-12, 2014 at the Moscone Center South in San Francisco, California in Booth 918. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend.

CytoSorbents Reports on Successful DIVI 2013 Conference
Marketwire - Mon Dec 16, 7:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.

Biocon Partners With CytoSorbents to Market CytoSorb(R) -- A 'First-in-Class' Therapy for Sepsis Management
Marketwire - Fri Sep 13, 7:01AM CDT
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb(R), a novel therapy for the management of sepsis.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 8

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 5

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 39

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

Amicus Therapeutics Plans Third Quarter 2025 Earnings Call

Updated Category News Views 159

Amicus Therapeutics to Discuss Q3 2025 Financial Results Amicus Therapeutics (NASDAQ: FOLD) is preparing for an important financial discussion as it will host a conference call on November 4, 2025, at 8:30 a.m. ET. This call aims to provide insights into the company’s financial performance for the quarter ending September 30, 2025. Conference Call Participation...

Continue Reading
Cineplex Inc. Hits New Milestones In Q2 2025 Financials

Updated Category News Views 223

Cineplex Reports Impressive Growth in Second Quarter Financials Cineplex Inc. (TSX: CGX) has announced its financial performance for the second quarter of 2025, revealing remarkable growth across various metrics. The company’s total revenues surged to CAD 361.8 million, representing a robust 30.5% increase compared to the same period last year. This performance can be...

Continue Reading
Pinnacle Mergers & Acquisitions Finalizes $151M Deal with Dream Motor Group

Updated Category News Views 545

Pinnacle Mergers & Acquisitions Completes a Major Sale DALLAS — Pinnacle Mergers & Acquisitions, a premier automotive buy-sell advisory firm, has finalized the significant sale of Toyota of Montgomery and Lexus of Montgomery to the renowned Dream Motor Group, led by famed coach Nick Saban and automotive expert Joe Agresti. The deal is valued at an impressive $151...

Continue Reading
Atria Development Corporation Appoints New Vice President

Updated Category News Views 80

Atria Development Corporation Welcomes New Leadership Atria Development Corporation is thrilled to announce that Durval Terceira has been appointed as the new Vice President of Business Development and Labour Relations. With his impressive background, he brings a wealth of experience that is expected to steer the company towards its future goals. Durval Terceira: An...

Continue Reading
Ark Invest's Strategic Shift: Selling Block Inc. Shares

Updated Category News Views 289

Ark Invest Adjusts Its Strategy Cathie Wood's Ark Invest has recently made headlines by selling off a portion of its holdings in Block Inc. This decision, valued at an impressive $4.8 million, signifies a potential shift in investment strategy ahead of Block's forthcoming earnings report. Investors are closely monitoring this move as it coincides with Block's rising...

Continue Reading